Because Orthobiologics spans various markets and is used in numerous procedures in different surgical settings, Q2 proved to be a roller coaster of a quarter, creating uncertainty and craziness. Beginning in mid-March with stay-at-home orders and restrictions on elective surgery, US elective procedures bottomed in April, resulting in plummeting revenues and increased angst.
Responding quickly to the new twists and turns of COVID-19, many companies shifted priorities, reduced costs and implemented initiatives to help climb out of the record-breaking descent of Q220. Revenue and procedural recovery varied widely and impacted segments differently.
Among the many topics covered in the comprehensive Q220 OrthoBio Market Recap* are:
- Complete OrthoBio Market Overview with Companies' Revenues and Shares
- The Ups and Downs of the US Bone Replacement Market
- The Twists and Turns of the US Soft Tissue Market
- Riding Out 2020
- Consumer Behavior
- Surgery/Surgeon Trends
- The US Economy
- Notable Developments in Q220
- Q220 Regulatory Highlights
Like a roller coaster, Q220 was a period of drastic changes that occurred without much warning, causing the blood to pump and the adrenaline to flow. Moving forward SmartTRAK projects that the market will ...